Endo International (NASDAQ:ENDP) (TSE:ENL) released its earnings results on Wednesday. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.17, RTT News reports. Endo International had a negative return on equity of 99.08% and a negative net margin of 16.89%. The firm had revenue of $764.80 million during the quarter, compared to analysts’ expectations of $730.15 million. During the same quarter last year, the business posted $0.75 earnings per share. The firm’s revenue was down 2.7% on a year-over-year basis. Endo International updated its FY 2020
Pre-Market guidance to 2.15-2.40 EPS and its FY20 guidance to $2.15-2.40 EPS.
Shares of NASDAQ ENDP opened at $5.94 on Thursday. The business’s 50 day moving average price is $5.89 and its 200-day moving average price is $4.46. Endo International has a fifty-two week low of $1.97 and a fifty-two week high of $12.49. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -2.70 and a beta of 1.48.
A number of brokerages recently commented on ENDP. BidaskClub raised Endo International from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. ValuEngine raised Endo International from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Finally, Piper Jaffray Companies raised Endo International from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $5.00 to $7.00 in a research note on Friday, January 3rd. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company. Endo International currently has a consensus rating of “Hold” and an average target price of $7.38.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
See Also: What causes a stock to be most active?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.